{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:20:18Z","timestamp":1789906818797,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1124\/jpet.120.000291","type":"journal-article","created":{"date-parts":[[2020,10,30]],"date-time":"2020-10-30T18:35:14Z","timestamp":1604082914000},"page":"29-39","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III"],"prefix":"10.1016","volume":"376","author":[{"given":"Sagnik","family":"Chatterjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sambuddho","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.V.J.","family":"Sankara Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanvi","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashyendra Singh","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bokka Venkata","family":"Murali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avinash Annasao","family":"Hadambar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gowtham Raj","family":"Gunti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijaykumar","family":"Kuchibhotla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Avisek","family":"Deyati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sushma","family":"Basavanthappa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manjunath","family":"Ramarao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. Thanga","family":"Mariappan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley A.","family":"Zinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sinz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.120.000291_bib1","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1002\/cpt.997","article-title":"Transporter-mediated alterations in patients with NASH increase systemic and hepatic exposure to an OATP and MRP2 substrate","volume":"104","author":"Ali","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.120.000291_bib2","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/bcp.12326","article-title":"Urinary coproporphyrin I\/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance","volume":"78","author":"Benz-de Bretagne","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.120.000291_bib3","doi-asserted-by":"crossref","first-page":"15080","DOI":"10.1038\/nrdp.2015.80","article-title":"Nonalcoholic fatty liver disease","volume":"1","author":"Brunt","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1124\/jpet.120.000291_bib4","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/jpet.120.000291_bib5","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"key":"10.1124\/jpet.120.000291_bib6","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.2337\/db14-1947","article-title":"Mechanism of altered metformin distribution in nonalcoholic steatohepatitis","volume":"64","author":"Clarke","year":"2015","journal-title":"Diabetes"},{"key":"10.1124\/jpet.120.000291_bib7","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1124\/jpet.113.211284","article-title":"Experimental nonalcoholic steatohepatitis increases exposure to simvastatin hydroxy acid by decreasing hepatic organic anion transporting polypeptide expression","volume":"348","author":"Clarke","year":"2014","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000291_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jhep.2014.02.021","article-title":"Synergistic interaction between genetics and disease on pravastatin disposition","volume":"61","author":"Clarke","year":"2014","journal-title":"J Hepatol"},{"key":"10.1124\/jpet.120.000291_bib9","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1111\/liv.13362","article-title":"Impaired N-linked glycosylation of uptake and efflux transporters in human non-alcoholic fatty liver disease","volume":"37","author":"Clarke","year":"2017","journal-title":"Liver Int"},{"key":"10.1124\/jpet.120.000291_bib10","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1124\/jpet.114.220764","article-title":"Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis","volume":"352","author":"Dzierlenga","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000291_bib11","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1124\/jpet.116.234310","article-title":"Biliary elimination of Pemetrexed is dependent on Mrp2 in rats: potential mechanism of variable response in nonalcoholic steatohepatitis","volume":"358","author":"Dzierlenga","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000291_bib12","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/cpt.1115","article-title":"Disease-associated changes in drug transporters may impact the pharmacokinetics and\/or toxicity of drugs: a white paper from the international transporter consortium","volume":"104","author":"Evers","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.120.000291_bib13","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jchromb.2018.12.023","article-title":"Relative quantitation of endogenous proteins by quadrupole-time of flight and tandem mass spectrometry","volume":"1106\u20131107","author":"Gautam","year":"2019","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/jpet.120.000291_bib14","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1124\/dmd.116.074740","article-title":"Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay","volume":"45","author":"Gilibili","year":"2017","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000291_bib15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/toxsci\/kfu156","article-title":"Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis","volume":"142","author":"Hardwick","year":"2014","journal-title":"Toxicol Sci"},{"key":"10.1124\/jpet.120.000291_bib16","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0016-5085(76)80322-8","article-title":"Coproporphyrin isomers in Dubin-Johnson syndrome","volume":"70","author":"Kondo","year":"1976","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.120.000291_bib17","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1007\/s40262-018-0648-3","article-title":"Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug\u2013drug interactions","volume":"57","author":"Kunze","year":"2018","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.120.000291_bib18","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.bcp.2016.07.001","article-title":"Effect of nonalcoholic steatohepatitis on renal filtration and secretion of adefovir","volume":"115","author":"Laho","year":"2016","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/jpet.120.000291_bib19","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.116.234914","article-title":"Coproporphyrins in plasma and urine can be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition","volume":"358","author":"Lai","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000291_bib20","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/toxsci\/kfx253","article-title":"Asking the right questions with animal models: methionine- and choline-deficient model in predicting adverse drug reactions in human NASH","volume":"161","author":"Li","year":"2018","journal-title":"Toxicol Sci"},{"key":"10.1124\/jpet.120.000291_bib21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1124\/dmd.107.015107","article-title":"Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease","volume":"35","author":"Lickteig","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000291_bib22","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1755-1536-6-19","article-title":"Experimental liver fibrosis research: update on animal models, legal issues and translational aspects","volume":"6","author":"Liedtke","year":"2013","journal-title":"Fibrogenesis Tissue Repair"},{"key":"10.1124\/jpet.120.000291_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41424-018-0034-3","article-title":"Bile acid metabolism and signaling: potential therapeutic target for nonalcoholic fatty liver disease","volume":"9","author":"Lin","year":"2018","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1124\/jpet.120.000291_bib24","doi-asserted-by":"crossref","first-page":"G449","DOI":"10.1152\/ajpgi.00199.2012","article-title":"Animal models of chronic liver diseases","volume":"304","author":"Liu","year":"2013","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1124\/jpet.120.000291_bib25","series-title":"The International Liver Congress 2019: Annual Meeting of the European Association for the Study of the Liver","article-title":"Pegbelfermin (BMS-986036) reduces serum levels of secondary bile acids in patient with non-alcoholic steatohepatitis","author":"Luo","year":"2019"},{"key":"10.1124\/jpet.120.000291_bib26","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1002\/hep.510310319","article-title":"Zonal down-regulation and redistribution of the multidrug resistance protein 2 during bile duct ligation in rat liver","volume":"31","author":"Paulusma","year":"2000","journal-title":"Hepatology"},{"key":"10.1124\/jpet.120.000291_bib27","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1039\/C3TX50069A","article-title":"A reversible model for periportal fibrosis and a refined alternative to bile duct ligation","volume":"3","author":"Probert","year":"2014","journal-title":"Toxicol Res"},{"key":"10.1124\/jpet.120.000291_bib28","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1002\/hep.29359","article-title":"The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids","volume":"67","author":"Puri","year":"2018","journal-title":"Hepatology"},{"key":"10.1124\/jpet.120.000291_bib29","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1124\/jpet.116.232066","article-title":"Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species","volume":"357","author":"Shen","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.120.000291_bib30","doi-asserted-by":"crossref","first-page":"114664","DOI":"10.1016\/j.taap.2019.114664","article-title":"Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis","volume":"379","author":"Suga","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1124\/jpet.120.000291_bib31","doi-asserted-by":"crossref","first-page":"C613","DOI":"10.1152\/ajpcell.00341.2004","article-title":"Cochlear gap junctions coassembled from Cx26 and 30 show faster intercellular Ca2+ signaling than homomeric counterparts","volume":"288","author":"Sun","year":"2005","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1124\/jpet.120.000291_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s11095-019-2593-8","article-title":"Recovery of OATP1B activity after living kidney transplantation in patients with end-stage renal disease","volume":"36","author":"Suzuki","year":"2019","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.120.000291_bib33","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s11095-010-0203-x","article-title":"Evaluation of (99m)technetium-mebrofenin and (99m)technetium-sestamibi as specific probes for hepatic transport protein function in rat and human hepatocytes","volume":"27","author":"Swift","year":"2010","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.120.000291_bib34","first-page":"52438","article-title":"Bile duct ligation in mice: induction of inflammatory liver injury and fibrosis by obstructive cholestasis","volume":"96","author":"Tag","year":"2015","journal-title":"J Vis Exp"},{"key":"10.1124\/jpet.120.000291_bib35","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1093\/oxfordjournals.jbchem.a122346","article-title":"Effect of bile duct ligation on bile acid and cholesterol metabolism in rats","volume":"103","author":"Takita","year":"1988","journal-title":"J Biochem"},{"key":"10.1124\/jpet.120.000291_bib36","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/j.xphs.2017.04.053","article-title":"Effect of liver disease on hepatic transporter expression and function","volume":"106","author":"Thakkar","year":"2017","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.120.000291_bib37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1297","article-title":"Acute hepatic porphyrias: review and recent progress","volume":"3","author":"Wang","year":"2018","journal-title":"Hepatol Commun"},{"key":"10.1124\/jpet.120.000291_bib38","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1124\/dmd.114.061580","article-title":"Interspecies variability in expression of hepatobiliary transporters across human, dog, monkey, and rat as determined by quantitative proteomics","volume":"43","author":"Wang","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.120.000291_bib39","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0002-9343(76)90426-5","article-title":"Rotor\u2019s syndrome. A distinct inheritable pathophysiologic entity","volume":"60","author":"Wolkoff","year":"1976","journal-title":"Am J Med"},{"key":"10.1124\/jpet.120.000291_bib40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1002\/cpt.1699","article-title":"Quantitative proteomics and mechanistic modeling of transporter-mediated disposition in nonalcoholic fatty liver disease","volume":"107","author":"Vildhede","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.120.000291_bib41","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1177\/0023677214558701","article-title":"A comparison of two common bile duct ligation methods to establish hepatopulmonary syndrome animal models","volume":"49","author":"Yang","year":"2015","journal-title":"Lab Anim"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524257360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.120.000291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T13:53:47Z","timestamp":1739973227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524257360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0022356524257360"],"URL":"https:\/\/doi.org\/10.1124\/jpet.120.000291","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.120.000291","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}